The role of somatic JAK2 mutations in clonal myeloproliferative neoplasms (MPNs) is well established. Recently, germ line JAK2 mutations were associated with polyclonal hereditary thrombocytosis and triple-negative MPNs. We studied a patient who inherited 2 heterozygous JAK2 mutations, E846D from the mother and R1063H from the father, and exhibited erythrocytosis and megakaryocytic atypia but normal platelet number. Culture of erythroid progenitors from the patient and his parents revealed hypersensitivity to erythropoietin (EPO). Using cellular models, we show that both E846D and R1063H variants lead to constitutive signaling (albeit much weaker than JAK2 V617F), and both weakly hyperactivate JAK2/STAT5 signaling only in the specific context of the EPO receptor (EPOR). JAK2 E846D exhibited slightly stronger effects than JAK2 R1063H and caused prolonged EPO-induced phosphorylation of JAK2/STAT5 via EPOR. We propose that JAK2 E846D predominantly contributes to erythrocytosis, but is not sufficient for the full pathological phenotype to develop. JAK2 R1063H, with very weak effect on JAK2/STAT5 signaling, is necessary to augment JAK2 activity caused by E846D above a threshold level leading to erythrocytosis with megakaryocyte abnormalities. Both mutations were detected in the germ line of rare polycythemia vera, as well as certain leukemia patients, suggesting that they might predispose to hematological malignancy.

CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences Vienna Austria

Department of Biology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic;

Department of Biology Faculty of Medicine and Dentistry Palacký University Olomouc Czech Republic; Signal Transduction and Molecular Hematology Unit Ludwig Institute for Cancer Research Brussels Belgium; de Duve Institute Université catholique de Louvain Brussels Belgium;

Department of Pediatrics University Hospital and Faculty of Medicine and Dentistry Olomouc Czech Republic; and

Signal Transduction and Molecular Hematology Unit Ludwig Institute for Cancer Research Brussels Belgium; de Duve Institute Université catholique de Louvain Brussels Belgium;

References provided by Crossref.org

A novel germline hyperactivating JAK2 mutation L604F

Experimental Modeling of Myeloproliferative Neoplasms

Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera